COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04468971

Tara Sadeghi

tara.sadeghi@cellenkosinc.com

2020-07-13

Completed

RCT

Randomized

Parallel

Blind label

multi-center

Treatment

inclusion criteria: - documented to have an rt-pcr-based diagnosis of sars-cov-2 infection by rt-pcr - moderate-to-severe ards as defined by the berlin criteria: ratio of partial pressure of arterial oxygen (pao2) to the fraction of inspired oxygen (fio2) of 200 mm hg or less assessed with a positive end-expiratory pressure (peep) of >5 cm h2o. - intubated for less than 120 hours - age ≥18 years - ability to provide informed consent or duly appointment health care proxy with the authority to provide informed consent.

in the opinion of the investigator, unlikely to survive for >48 hours from screening. any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study. currently receiving extracorporeal membrane oxygenation (ecmo) or high frequency oscillatory ventilation (hfov). females who are pregnant. patients with active bacteremia at start of therapy enrollment or concurrently active moderate to severe other infectious which in the opinion of the investigator may possibly affect the safety of ck0802 treatment. patients who have been intubated for more than 120 hours. known hypersensitivity to dmso or to porcine or bovine protein. any end-stage organ disease which in the opinion of the investigator may possibly affect the safety of ck0802 treatment. high dose steroids. receiving an investigational cellular therapy agent.

3

Cellenkos, Inc.

18

100

United States

Severe/critical disease at enrollment

7: Severe/critical disease at enrollment

45

Regimen related ≥ grade 3 toxicity within 48 hours of first infusion;28-day treatment success, defined as S28

None

Phase 1

[{"arm_notes": "", "treatment_id": 358, "treatment_name": "Cryopreserved cord blood derived t-regulatory cell infusions (ck0802)", "treatment_type": "Advanced therapy medicinal products (atmp)", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 358, "treatment_name": "Cryopreserved cord blood derived t-regulatory cell infusions (ck0802)", "treatment_type": "Advanced therapy medicinal products (atmp)", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]